Effect of antibiotics against Mycoplasma sp. on human embryonic stem cells undifferentiated status, pluripotency, cell viability and growth.

Human embryonic stem cells (hESCs) are self-renewing pluripotent cells that can differentiate into specialized cells and hold great promise as models for human development and disease studies, cell-replacement therapies, drug discovery and in vitro cytotoxicity tests. The culture and differentiation...

Full description

Bibliographic Details
Main Authors: Leonardo Romorini, Diego Ariel Riva, Carolina Blüguermann, Guillermo Agustin Videla Richardson, Maria Elida Scassa, Gustavo Emilio Sevlever, Santiago Gabriel Miriuka
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3728093?pdf=render
id doaj-5f09bfd164cd4ef5ab6a0ead1a83e637
record_format Article
spelling doaj-5f09bfd164cd4ef5ab6a0ead1a83e6372020-11-25T02:22:53ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0187e7026710.1371/journal.pone.0070267Effect of antibiotics against Mycoplasma sp. on human embryonic stem cells undifferentiated status, pluripotency, cell viability and growth.Leonardo RomoriniDiego Ariel RivaCarolina BlüguermannGuillermo Agustin Videla RichardsonMaria Elida ScassaGustavo Emilio SevleverSantiago Gabriel MiriukaHuman embryonic stem cells (hESCs) are self-renewing pluripotent cells that can differentiate into specialized cells and hold great promise as models for human development and disease studies, cell-replacement therapies, drug discovery and in vitro cytotoxicity tests. The culture and differentiation of these cells are both complex and expensive, so it is essential to extreme aseptic conditions. hESCs are susceptible to Mycoplasma sp. infection, which is hard to detect and alters stem cell-associated properties. The purpose of this work was to evaluate the efficacy and cytotoxic effect of Plasmocin(TM) and ciprofloxacin (specific antibiotics used for Mycoplasma sp. eradication) on hESCs. Mycoplasma sp. infected HUES-5 884 (H5 884, stable hESCs H5-brachyury promoter-GFP line) cells were effectively cured with a 14 days Plasmocin(TM) 25 µg/ml treatment (curative treatment) while maintaining stemness characteristic features. Furthermore, cured H5 884 cells exhibit the same karyotype as the parental H5 line and expressed GFP, through up-regulation of brachyury promoter, at day 4 of differentiation onset. Moreover, H5 cells treated with ciprofloxacin 10 µg/ml for 14 days (mimic of curative treatment) and H5 and WA09 (H9) hESCs treated with Plasmocin(TM) 5 µg/ml (prophylactic treatment) for 5 passages retained hESCs features, as judged by the expression of stemness-related genes (TRA1-60, TRA1-81, SSEA-4, Oct-4, Nanog) at mRNA and protein levels. In addition, the presence of specific markers of the three germ layers (brachyury, Nkx2.5 and cTnT: mesoderm; AFP: endoderm; nestin and Pax-6: ectoderm) was verified in in vitro differentiated antibiotic-treated hESCs. In conclusion, we found that Plasmocin(TM) and ciprofloxacin do not affect hESCs stemness and pluripotency nor cell viability. However, curative treatments slightly diminished cell growth rate. This cytotoxic effect was reversible as cells regained normal growth rate upon antibiotic withdrawal.http://europepmc.org/articles/PMC3728093?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Leonardo Romorini
Diego Ariel Riva
Carolina Blüguermann
Guillermo Agustin Videla Richardson
Maria Elida Scassa
Gustavo Emilio Sevlever
Santiago Gabriel Miriuka
spellingShingle Leonardo Romorini
Diego Ariel Riva
Carolina Blüguermann
Guillermo Agustin Videla Richardson
Maria Elida Scassa
Gustavo Emilio Sevlever
Santiago Gabriel Miriuka
Effect of antibiotics against Mycoplasma sp. on human embryonic stem cells undifferentiated status, pluripotency, cell viability and growth.
PLoS ONE
author_facet Leonardo Romorini
Diego Ariel Riva
Carolina Blüguermann
Guillermo Agustin Videla Richardson
Maria Elida Scassa
Gustavo Emilio Sevlever
Santiago Gabriel Miriuka
author_sort Leonardo Romorini
title Effect of antibiotics against Mycoplasma sp. on human embryonic stem cells undifferentiated status, pluripotency, cell viability and growth.
title_short Effect of antibiotics against Mycoplasma sp. on human embryonic stem cells undifferentiated status, pluripotency, cell viability and growth.
title_full Effect of antibiotics against Mycoplasma sp. on human embryonic stem cells undifferentiated status, pluripotency, cell viability and growth.
title_fullStr Effect of antibiotics against Mycoplasma sp. on human embryonic stem cells undifferentiated status, pluripotency, cell viability and growth.
title_full_unstemmed Effect of antibiotics against Mycoplasma sp. on human embryonic stem cells undifferentiated status, pluripotency, cell viability and growth.
title_sort effect of antibiotics against mycoplasma sp. on human embryonic stem cells undifferentiated status, pluripotency, cell viability and growth.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2013-01-01
description Human embryonic stem cells (hESCs) are self-renewing pluripotent cells that can differentiate into specialized cells and hold great promise as models for human development and disease studies, cell-replacement therapies, drug discovery and in vitro cytotoxicity tests. The culture and differentiation of these cells are both complex and expensive, so it is essential to extreme aseptic conditions. hESCs are susceptible to Mycoplasma sp. infection, which is hard to detect and alters stem cell-associated properties. The purpose of this work was to evaluate the efficacy and cytotoxic effect of Plasmocin(TM) and ciprofloxacin (specific antibiotics used for Mycoplasma sp. eradication) on hESCs. Mycoplasma sp. infected HUES-5 884 (H5 884, stable hESCs H5-brachyury promoter-GFP line) cells were effectively cured with a 14 days Plasmocin(TM) 25 µg/ml treatment (curative treatment) while maintaining stemness characteristic features. Furthermore, cured H5 884 cells exhibit the same karyotype as the parental H5 line and expressed GFP, through up-regulation of brachyury promoter, at day 4 of differentiation onset. Moreover, H5 cells treated with ciprofloxacin 10 µg/ml for 14 days (mimic of curative treatment) and H5 and WA09 (H9) hESCs treated with Plasmocin(TM) 5 µg/ml (prophylactic treatment) for 5 passages retained hESCs features, as judged by the expression of stemness-related genes (TRA1-60, TRA1-81, SSEA-4, Oct-4, Nanog) at mRNA and protein levels. In addition, the presence of specific markers of the three germ layers (brachyury, Nkx2.5 and cTnT: mesoderm; AFP: endoderm; nestin and Pax-6: ectoderm) was verified in in vitro differentiated antibiotic-treated hESCs. In conclusion, we found that Plasmocin(TM) and ciprofloxacin do not affect hESCs stemness and pluripotency nor cell viability. However, curative treatments slightly diminished cell growth rate. This cytotoxic effect was reversible as cells regained normal growth rate upon antibiotic withdrawal.
url http://europepmc.org/articles/PMC3728093?pdf=render
work_keys_str_mv AT leonardoromorini effectofantibioticsagainstmycoplasmasponhumanembryonicstemcellsundifferentiatedstatuspluripotencycellviabilityandgrowth
AT diegoarielriva effectofantibioticsagainstmycoplasmasponhumanembryonicstemcellsundifferentiatedstatuspluripotencycellviabilityandgrowth
AT carolinabluguermann effectofantibioticsagainstmycoplasmasponhumanembryonicstemcellsundifferentiatedstatuspluripotencycellviabilityandgrowth
AT guillermoagustinvidelarichardson effectofantibioticsagainstmycoplasmasponhumanembryonicstemcellsundifferentiatedstatuspluripotencycellviabilityandgrowth
AT mariaelidascassa effectofantibioticsagainstmycoplasmasponhumanembryonicstemcellsundifferentiatedstatuspluripotencycellviabilityandgrowth
AT gustavoemiliosevlever effectofantibioticsagainstmycoplasmasponhumanembryonicstemcellsundifferentiatedstatuspluripotencycellviabilityandgrowth
AT santiagogabrielmiriuka effectofantibioticsagainstmycoplasmasponhumanembryonicstemcellsundifferentiatedstatuspluripotencycellviabilityandgrowth
_version_ 1724861340161409024